Merck R&D Renaissance To Continue With Three NDA Filings In 2007
During Dec. 12 investor meeting, Merck Research Labs President Peter Kim says firm will file NDAs for compounds to treat HIV, insomnia and atherosclerosis in 2007.
During Dec. 12 investor meeting, Merck Research Labs President Peter Kim says firm will file NDAs for compounds to treat HIV, insomnia and atherosclerosis in 2007.